Immunothérapie anticancer : les molécules immunomodulatrices en développement clinique

详细信息    查看全文

• 作者：D. Loirat ; C. Le Tourneau
• 关键词：Immunothérapie ; Immunodulateurs ; Essais cliniques ; Cancer ; Immunotherapy ; Immune checkpoint ; Clinical trials ; Cancer
• 刊名：Oncologie
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：17
• 期：9
• 页码：379-389
• 全文大小：196 KB
• 参考文献：1.Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39: 1-0CrossRef PubMed
  2.Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-4CrossRef PubMed
  3.Ceeraz S, Nowak EC, Noelle RJ (2013) B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 34: 556-3CrossRef PubMed
  4.Maker AV, Phan GQ, Attia P, et al. (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyteassociated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12: 1005-6PubMed Central CrossRef PubMed
  5.Hodi FS, O’Day SJ, McDermott DF, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-3PubMed Central CrossRef PubMed
  6.Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. (2015) Adjuvant ipilimumab versus placebo after complete resection of highrisk stage III melanoma (EORTC 18071): a randomised, doubleblind, phase III trial. Lancet Oncol 16: 522-0. doi:10.1016/S1470-045(15)70122-1CrossRef PubMed
  7.Kwon ED, Drake CG, Scher HI, et al. (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castrationresistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase III trial. Lancet Oncol 15: 700-2PubMed Central CrossRef PubMed
  8.Camacho LH, Antonia S, Sosman J, et al. (2009) Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27: 1075-1CrossRef PubMed
  9.Chung KY, Gore I, Fong L, et al. (2010) Phase II study of the anticytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol 28: 3485-0CrossRef PubMed
  10.Kirkwood JM, Lorigan P, Hersey P, et al. (2010) Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 16: 1042-CrossRef PubMed
  11.Calabrò L, Morra A, Fonsatti E, et al. (2015) Efficacy and safety of an intensified schedule of tremelimumab for chemotherapyresistant malignant mesothelioma: an open-label, single-arm, phase II study. Lancet Respir Med 3: 301-. doi:10.1016/S2213-2600(15)00092-2CrossRef PubMed
  12.Ribas A, Kefford R, Marshall MA, et al. (2013) Phase III randomized clinical trial comparing tremelimumab with standardof- care chemotherapy in patients with advanced melanoma. J Clin Oncol 31: 616-2CrossRef PubMed
  13.Freeman GJ, Long AJ, Iwai Y, et al. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-4PubMed Central CrossRef PubMed
  14.Zou W, Chen L (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8: 467-7CrossRef PubMed
  15.Topalian SL, Hodi FS, Brahmer JR, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-4PubMed Central CrossRef PubMed
  16.National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). http://?evs.?nci.?nih.?gov/?ftp1/?CTCAE/-/cite>
  17.Robert C, Long GV, Brady B, et al. (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372: 320-0CrossRef PubMed
  18.Postow MA, Chesney J, Pavlick AC, et al. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 373: 23-4. doi:10.1056/NEJMoa1504030CrossRef PubMed
  19.Gettinger SN, Horn L, Gandhi L, et al. (2015) Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33: 2004-2. doi: 10.1200/JCO.2014.58.3708CrossRef PubMed
  20.Brahmer J, Reckamp KL, Baas P, et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373: 123-5CrossRef PubMed
  21.Robert C, Schachter J, Long GV, et al. (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372: 2521-2. doi:10.1056/NEJMoa1503093CrossRef PubMed
  22.Robert C, Ribas A, Wolchok JD, et al. (2014) Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dosecomparison cohort of a phase I trial. Lancet 384: 1109-7CrossRef PubMed
  23.Garon EB, Rizvi NA, Hui R, et al. (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372: 2018-8. doi:10.1056/NEJMoa1501824CrossRef PubMed
  24.Brahmer JR, Tykodi SS, Chow LQM, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-5PubMed Central CrossRef PubMed
  25.Segal NH, Hamid O, Hwu W, et al. (2014) A phase I multi-arm dose-expansion study of the anti-programmed cell death-ligand-1 (PD-L1)
• 作者单位：D. Loirat (1) (2)
  C. Le Tourneau (1) (3)
  
  1. Département d’oncologie médicale, institut Curie, F-75005 Paris et F-92210, Saint-Cloud, France
  2. Translational Immunotherapy Team, Inserm U932, département de transferts, institut Curie, F-75005, Paris, France
  3. Inserm U900, Institut Curie, F-75005, Paris, France
  
• 刊物主题：Oncology;
• 出版者：Springer Paris
• ISSN：1765-2839

文摘

Immune response often fails to control tumor development due to the activation of inefficient lymphocyte or tolerization mechanisms. The goal of immunotherapeutics is to reverse the balance between the immune response and tumor growth. Targeting immune checkpoints involved in the activation or inhibition pathways of specific immune response is an emerging strategy. It has shown promising results for metastatic melanoma with antibodies targeting CTLA4, and more recently with antibodies targeting PD- 1/PD-L1 in melanoma and also other types of tumor. Therapies targeting B7 family members (CTLA4, PD-1, PD-L1/2, etc.) are the most advanced in clinical development, but molecules belonging to TNF-R family (OX40, CD40, GITR, CD137, etc.) also appear to be promising. In this article, we present a review of the different pathways involved in immune response modulation and corresponding therapeutic agents under clinical development. Keywords Immunotherapy Immune checkpoint Clinical trials Cancer